Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Kamal S. Saini(Cambridge University Hospitals NHS Foundation Trust), Martine Piccart(Université Libre de Bruxelles)

Cancer Treatment Reviews

May 3, 2013

10.1016/j.ctrv.2013.03.009

Cited by 378

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

|The Lancet|2014|4.7k

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

|Annals of Oncology|2016|2.1k

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

|New England Journal of Medicine|2016|2k

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

|Annals of Oncology|2015|1.8k

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

|The Lancet|2007|1.5k